Immatics Q2 2026: SUPRAME Trial Redesign, Cash Runway into 2028, and Updated Clinical Data
IMTX sits 83% above its 52-week low of $5.05 on elevated volume (2.3× avg).
Summary
Immatics reported Q2 2026 results with $448.2M in cash and a runway into 2028. The company announced a streamlined final analysis for the SUPRAME Phase 3 trial, maintaining 90% power for PFS while increasing enrollment to ~450 patients to strengthen OS data. Updated clinical data for anzu-cel and IMA203CD8 were also presented.
Key Events · Earnings and Guidance · IMTX
-
SUPRAME Trial Redesign
Immatics will replace the previously planned interim and final PFS analyses with a single streamlined final analysis, based on a lower prespecified number of PFS events while maintaining 90% power. Enrollment will increase by ~90 patients to ~450 total to strengthen the secondary OS endpoint.
-
Cash Position and Runway
Cash and cash equivalents plus other financial assets totaled $448.2M (€393.4M) as of June 30, 2026, down from $534.7M (€469.3M) at year-end 2025. Management projects cash runway into 2028.
-
Anzu-cel Updated Phase 1b Data
Updated data from ASCO 2026 showed 56% confirmed ORR, 14.6 months median duration of response, 6.1 months median PFS, 16.2 months median OS, and a 2-year OS rate of 46% in metastatic melanoma.
-
IMA203CD8 Updated Phase 1 Data
In gynecologic cancers, IMA203CD8 showed 63% ORR and 50% confirmed ORR with 4 complete responses. In synovial sarcoma, it showed 67% ORR and 64% confirmed ORR with responses lasting up to ~3 years.
Analysis · IMTX · Life Sciences
Immatics reported Q2 2026 results with $448.2M in cash and a runway into 2028, but the key development is the SUPRAME Phase 3 trial redesign. Slower-than-expected PFS events led the company to replace interim and final analyses with a single streamlined final analysis, while increasing enrollment by ~90 patients to ~450 to boost OS power. This maintains a 90% power for the primary PFS endpoint and keeps the topline data readout on track for H1 2027, followed by a BLA submission in 2027. The filing also includes updated Phase 1b data for anzu-cel showing durable responses (56% cORR, 14.6 months mDOR, 16.2 months mOS) and Phase 1 data for IMA203CD8 in gynecologic cancers and synovial sarcoma. The trial redesign is a material update that could affect the timing and interpretation of the pivotal data, making this a significant event for investors.
At the time of this filing, IMTX was trading at $9.25 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $1.2B. The 52-week trading range was $5.05 to $12.41. This filing was assessed with neutral market sentiment and an importance score of 8 out of 10.